Fetal hemoglobin (Hb F) levels increase in the majority of sickle cell patients following intermittent butyrate therapy. Although the full effects of butyrate on Hb F levels usually require multiple treatment cycles, in some patients, a peak level is achieved after a few days of butyrate therapy. Our investigation of the mechanism(s) responsible for this rapid induction of Hb F by butyrate showed that reticulocyteglobin chain synthesis markedly increased within 24 hours of butyrate exposure, without concomitant changes in reticulocyte -globin mRNA levels. This suggests that butyrate might induce Hb F by increasing the efficiency of translation of -globin mRNA. This hypothesis was confirmed by ribosome loading studies that demonstrated enrichment of the polysomal fraction of reticulocytes with -globin mRNA following butyrate exposure. Thus, the induction of Hb F by butyrate may be mediated by translational effects in addition to its well-known effects on transcription of the -globin genes.
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Abstract:
Fetal hemoglobin (Hb F) levels increase in the majority of sickle cell patients following intermittent butyrate therapy. Although the full effects of butyrate on Hb F levels usually require multiple treatment cycles, in some patients, a peak level is achieved after a few days of butyrate therapy. Our investigation of the mechanism(s) responsible for this rapid induction of Hb F by butyrate showed that reticulocyteglobin chain synthesis markedly increased within 24 hours of butyrate exposure, without concomitant changes in reticulocyte -globin mRNA levels. This suggests that butyrate might induce Hb F by increasing the efficiency of translation of -globin mRNA. This hypothesis was confirmed by ribosome loading studies that demonstrated enrichment of the polysomal fraction of reticulocytes with -globin mRNA following butyrate exposure. Thus, the induction of Hb F by butyrate may be mediated by translational effects in addition to its well-known effects on transcription of the -globin genes.
Introduction:
During normal ontogeny, fetal hemoglobin (Hb F) is gradually replaced by adult hemoglobin due to a switch from -to -globin gene expression. Patients with SCD (SCD) and -thalassemia who have genetically-determined high levels of Hb F generally have a mild clinical disorder [1] [2] [3] . This suggested that induction of Hb F in adult life might be an effective form of treatment for patients with SCD. Subsequent studies showed that hypomethylating agents (e.g. 5-azacytidine) 4, 5 , cytotoxic agents (e.g. hydroxyurea) [6] [7] [8] [9] [10] [11] [12] [13] , and inhibitors of histone deacetylase (e.g. butyrate)
14-17 can increase Hb F in patients with SCD. 19, 20 , delay the switch from fetal to adult hemoglobin in sheep exposed to butyrate in utero 21 , and increase Hb F levels in adult baboons 22, 24 . In clinical trials, intravenous infusions of arginine butyrate [14] [15] [16] and oral administration of sodium phenylbutrate 17 increased Hb F in patients with SCD andthalassemia. More recently, our own studies showed that intermittent therapy with arginine butyrate resulted in a sustained marked induction of Hb F in 9 of 11 patients with SCD
14
.
The mechanisms by which butyrate increases -globin expression have not been fully elucidated. Since butyrate is a known inhibitor of histone deacetylase, it is widely assumed, though never proven, that butyrate increases Hb F levels by increasing the transcription of the -globin through changes in histone acetylation 23, 24 . In most patients who receive butyrate, Hb F levels increase gradually over several months of therapy 14 . However, in some patients, Hb F levels increase within few days of initiating butyrate therapy. The kinetics of this rapid increase are not compatible with transcriptional effects in nucleated erythroid precursors in the bone marrow. This prompted us to explore other mechanism(s) that might result in a rapid increase in Hb F levels in SCD.
Materials and Methods:
Patients and treatment: According to the Declaration of Helsinki, informed consent was obtained from all patients. All procedures were approved by the Institutional Review Board of the Mount Sinai School of Medicine. Studies were performed on peripheral blood from 7 adult patients with SCD who were enrolled in a
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From study of intermittent arginine butyrate therapy 14 . Blood was collected pre-treatment and at timed intervals during butyrate therapy.
Reticulocyte -globin chain synthesis: As previously described 25, 26 , washed red blood cells were incubated in medium containing Polysomal distribution of -globin mRNA: Red blood cells were washed, lysed, centrifuged on a sucrose gradient and fractionated as previously described 28 . The gradients were collected in 15 fractions and the -globin and -globin mRNA levels in each fraction were also determined by RPA.
Results and Discussion:
We measured -globin chain synthesis and mRNA levels in patients' reticulocytes pre-treatment and at timed intervals after initiation of butyrate infusions.
Detailed data from a representative butyrate responsive patient is presented in
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From Figure 1A . Reticulocyte -globin chain synthesis increased from 1.9% to 6.7% (3.5 fold increase) at 26 hours after initiation of infusion. In contrast, there was no significant change in -globin mRNA levels during that time ( Figure 1B) . Data from this patient, 4 other butyrate responsive patients and 2 butyrate non-responsive patients are summarized in Figure 1 C & D. In butyrate responsive patients, mean reticulocyte -globin chain synthesis increased from 2.6 ± 1.9% pretreatment to 6.5 ± 2.0% (p=0.004) within 24 hours after initiation of infusion ( Figure 1C ). In contrast, there was no significant change in -globin mRNA levels during that time (13.4 ± 5.6 pretreatment vs. 15.0 ± 6.9% at 24 hours, p=0.57) ( Figure 1D ). In these butyrateresponsive patients, the increase in -globin protein chain synthesis was very rapid, occurring within 2 days of beginning therapy in all patients (data not shown). In contrast, there was no change in -globin protein chain synthesis or -globin mRNA in butyrate non-responsive patients ( Figures 1C and 1D ). This rapid increase inglobin protein chain synthesis was not associated with consistent changes in mRNA levels (1B and 1D). These observations suggest that the rapid increase in -globin chain synthesis is most likely a result of an increase in the efficiency of translation of -globin mRNA.
We then investigated the effect of butyrate on the efficiency of mRNA translation. In the first patient we studied, reticulocyte -globin protein chain synthesis increased by 4-fold (from 1.03% to 3.96%) within 24 hours of butyrate infusion. Prepolysomal reticulocyte -globin mRNA decreased from 25% to 14% at 24 hours after treatment while polysomal mRNA increased from 29% to 37.6% (Figure 2A) , suggesting an increased efficiency of translation of -globin mRNA.
Interestingly, no polysomal shift was seen in this same patient during a butyrate
cycle that followed a serious infection when she did not respond by increasing her Hb F level (data not shown). In another patient we studied, Hb F increased modestly from 23.1% to 25.6% during the four-day treatment cycle. The prepolysomal -globin mRNA decreased from 36.1% pre-treatment to 22.3% at 24 hours while the polysomal mRNA increased from 26.5% to 35.1% (Fig. 2B) .
These studies provide experimental evidence in support of the hypothesis that the butyrate induced, rapid increase in Hb F levels is mediated by an increase in the efficiency of translation of -globin mRNA. This, of course, does not imply that butyrate induces Hb F levels solely through an effect on translation of -globin mRNA. The transcriptional effects of butyrate in nucleated erythroid precursors in the bone marrow would probably require a significantly longer time to increase the Hb F levels in the peripheral blood 15, 29 . The mechanism responsible for the increased efficiency of -globin mRNA translation is not yet known. Although our studies have shown that butyrate increases the efficiency of translation of -globin mRNA, but not that of -or -globin mRNA (data not shown), it is not clear whether other cellular mRNA's may be translated more efficiently in the presence of butyrate. We speculate that the effect of butyrate on the efficiency of mRNA translation may be a result of changes in the acetylation of proteins involved in mRNA translation. These questions and several others that are raised by our observations described above require further investigation. 
